Real-World Safety and Effectiveness of Oral Nucleos(t)ide Analogs in the Treatment of Chronic Hepatitis B Virus Infection

AbstractPurpose of ReviewChronic hepatitis B (CHB) remains a major global contributor to liver related morbidity and mortality. Currently available first line therapies offer all oral, highly effective, and safe treatment options for suppression of hepatitis B virus (HBV) and reduce long-term CHB-related complications. This review summarizes some of the more recent real-world data on the safety and effectiveness of oral nucleos(t)ide analogs in the treatment of CHB.Recent FindingsCurrent first line CHB oral treatment options include entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). Recent real-world evidence continues to emphasize the highly effective nature of these therapies in suppressing HBV DNA and normalization of alanine aminotransferase. While all of these oral nucleos(t)ide analogs are relatively safe and well-tolerated, we include some recent data illustrating the potential benefit of TAF among CHB patients at risk for chronic kidney disease or osteopenia/osteoporosis.SummaryWhile highly effective and safe oral antiviral therapies are available for CHB treatment, disparities in timely CHB diagnosis and linkage to care and treatment remain. Improvements in HBV screening for early CHB diagnosis as well as effective programs to link known CHB patients into care and treatment are urgently needed.
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research